Compare BioNTech SE - ADR (BNTX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Vanguard Information Technology Index Fund ETF — how do they compare? BioNTech SE - ADR trades at $93.35 (market cap $23.31B), while Vanguard Information Technology Index Fund ETF trades at $121.77. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | VGT | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | — |
52-Week High | $119.34 | $125.77 |
52-Week Low | $83.89 | $83.59 |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
VGT trades at $121.85, up 1.33% with strong bullish momentum from moving averages. The ETF benefits from institutional accumulation and positive AI infrastructure exposure. Technical indicators show RSI_6 at 82.74 suggesting overbought conditions while ADX signals strong trend strength. Recent news highlights institutional buying sprees and Microsoft's earnings boost to tech ETFs.
Outlook remains positive given institutional confidence and AI-driven growth, though concentration risk and overbought technicals warrant caution. The pure-tech focus has outperformed broader tech ETFs historically, but semiconductor volatility presents near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
